NEW YORK (360Dx) – Bio-Techne said today that it has inked a strategic agreement with Micropoint Bioscience, developer of a microfluidic chip for point-of-care testing based in Shenzhen, China.

Bio-Techne said that under the agreement, the firms will collaborate to strengthen the integration of its ProteinSimple Ella microfluidic instrument, a fully automated multianalyte immunoassay, to develop "better and more accurate" point-of-care diagnostic tools for the Chinese market.

Financial and other terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.